COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,785 Articles (22,523 medRxiv, 8,262 bioRxiv)

Most recent first Previous |  Page 425: Articles 4241-4250  | Next

Campus Sewage Water Surveillance based dynamics and infection trends of SARS-CoV-2 variants during third wave of COVID-19 in Pune, India
Dharne, M.
10.1101/2023.03.02.23286683 — Posted: 2023-03-05
Detection of SARS-CoV-2 in Schools Using Built Environment Testing in Ottawa, Canada: A Multi-Facility Prospective Surveillance Study
Thampi, N., Burhunduli, T., Strain, J., Raudanskis, A., Moggridge, J. A., Hinz, A., Doukhanine, E., Castellani, L., Fralick, M., Kassen, R., McCready, J., Nott, C., Wong, A., MacFadden, D. R.
10.1101/2023.03.03.23286750 — Posted: 2023-03-05
Decline in prevalence of tuberculosis following an intensive case-finding campaign and the COVID-19 pandemic in an urban Ugandan community
Kendall, E. A., Kitonsa, P. J., Nalutaaya, A., Robsky, K. O., Erisa, K. C., Mukiibi, J., Cattamanchi, A., Kato-Maeda, M., Katamba, A., Dowdy, D. W.
10.1101/2023.03.03.23286745 — Posted: 2023-03-05
Phenome-wide association study to explore the long-term symptoms after infection with novel coronavirus in the UK Biobank
Zhang, K., Liu, X., Fu, P., Zhao, Y., Yu, Q., Liu, S., Xue, F.
10.1101/2023.03.03.23286122 — Posted: 2023-03-05
Residual Sanitization of Three Human Respiratory Viruses on a Hard, Non-Porous Surface
Ikner, L. A., Rabe, A. B., Gerba, C. P.
10.1101/2023.03.02.530883 — Posted: 2023-03-03
Frequent emergence of resistance mutations following complex intra-host genomic dynamics in SARS-CoV-2 patients receiving Sotrovimab
Cabrera, R. P., Tejerina, F., Salinas, A. M., Ferris, M., Veintimilla, C., Catalan, P., Macias, G. R., Alonso, R., Munoz, P., Garcia de Viedma, D., Perez-Lago, L.
10.1101/2023.03.01.530733 — Posted: 2023-03-03
The infectivity of SARS-CoV-2 progeny virions requires the activity of host cell N-myristoyltransferases and it is severely compromised by their inhibition
Saber, S. H., Ojha, R., Quirin, T., Strandin, T., Yak, N., Kant, R., Kareinen, L., Sironen, T., Vapalahti, O., Balistreri, G., Joensuu, M.
10.1101/2023.03.03.530798 — Posted: 2023-03-03
Virological evidence of the impact of non-pharmaceutical interventions against COVID-19 in a resource-limited setting
Moreira-Soto, A., Bruno, A., de Mora, D., Paez, M., Garcez, J., Wulf, B., Sander, A.-L., Olmedo, M., Basantes Mantilla, M. J., Gonzalez, M., Orlando Narvaez, A., Salgado Cisneros, S. P., Zevallos, J. C., Drexler, J.
10.1101/2023.03.01.23286616 — Posted: 2023-03-03
Risk of cardiovascular events following COVID-19 in people with and without pre-existing chronic respiratory disease
Whittaker, H., Kallis, C., Wood, A., Bolton, T., Walker, S., Sheikh, A., Brownrigg, A., Akbari, A., Sterniczuk, K., Quint, J. K.
10.1101/2023.03.01.23286624 — Posted: 2023-03-03
MANAGEMENT OF RISK FACTORS FOR HEALTH CARE WORKERS AFTER INITIAL CONTACT WITH PATIENTS INFECTED WITH SARS-CoV-2 IN NIAMEY, THE CENTER OF THE EPIDEMIC IN NIGER
Ramatoulaye, H. L., Abdal-Kader, A. S., Lagare, A., Maiga, M., Aliane, F. A., Sylviane, F. C. A., Issa, I., Sidikou, B. A., Oumarou, G. I., Aouta, Z. A., Moussa, A., Alassan, Z. D., Karidjo, I., Bachir, G. A. M., Djibo, I., Moussa, S., Maman Laminou, i., Jambou, R.
10.1101/2023.03.01.23286420 — Posted: 2023-03-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).